Brokerages Set Pulmonx Co. (NASDAQ:LUNG) Target Price at $12.75

Shares of Pulmonx Co. (NASDAQ:LUNG) have received an average recommendation of “Moderate Buy” from the six research firms that are covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $12.75.

LUNG has been the topic of a number of research reports. Stifel Nicolaus dropped their price target on Pulmonx from $17.00 to $16.00 and set a “buy” rating on the stock in a research note on Thursday, October 31st. Wells Fargo & Company cut their target price on shares of Pulmonx from $10.00 to $8.00 and set an “equal weight” rating on the stock in a report on Wednesday, December 11th. Finally, Citigroup reiterated a “neutral” rating and set a $7.50 price target (down previously from $17.00) on shares of Pulmonx in a research note on Wednesday, December 11th.

Pulmonx Stock Performance

Shares of Pulmonx stock opened at $6.16 on Wednesday. The firm has a market capitalization of $243.25 million, a P/E ratio of -4.19 and a beta of 0.69. The company has a quick ratio of 6.77, a current ratio of 7.70 and a debt-to-equity ratio of 0.40. Pulmonx has a 52 week low of $5.46 and a 52 week high of $14.84. The firm’s 50 day moving average is $6.49 and its two-hundred day moving average is $6.84.

Pulmonx (NASDAQ:LUNG) last announced its quarterly earnings results on Wednesday, October 30th. The company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.07. Pulmonx had a negative net margin of 72.01% and a negative return on equity of 53.88%. The firm had revenue of $20.39 million for the quarter, compared to analyst estimates of $20.39 million. During the same period last year, the business earned ($0.39) EPS. Research analysts forecast that Pulmonx will post -1.53 EPS for the current fiscal year.

Insider Activity at Pulmonx

In related news, insider Geoffrey Beran Rose sold 4,376 shares of the firm’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $6.18, for a total value of $27,043.68. Following the completion of the sale, the insider now owns 291,057 shares in the company, valued at $1,798,732.26. This trade represents a 1.48 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, General Counsel David Aaron Lehman sold 5,497 shares of the business’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $6.19, for a total value of $34,026.43. Following the transaction, the general counsel now owns 197,851 shares in the company, valued at $1,224,697.69. The trade was a 2.70 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 49,873 shares of company stock worth $324,070 in the last three months. Insiders own 5.70% of the company’s stock.

Institutional Investors Weigh In On Pulmonx

Several institutional investors have recently made changes to their positions in the stock. 272 Capital LP acquired a new stake in shares of Pulmonx in the third quarter valued at about $25,000. nVerses Capital LLC acquired a new stake in shares of Pulmonx during the 3rd quarter valued at approximately $26,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Pulmonx during the 2nd quarter worth approximately $37,000. SG Americas Securities LLC acquired a new stake in shares of Pulmonx in the 3rd quarter worth approximately $102,000. Finally, Hsbc Holdings PLC purchased a new position in Pulmonx in the 2nd quarter valued at approximately $93,000. 91.04% of the stock is currently owned by hedge funds and other institutional investors.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.